These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1366021)

  • 21. Rapid reporting and review of an increased incidence of a known adverse event.
    Sargent DJ; Goldberg RM; Mahoney MR; Hillman DW; McKeough T; Hamilton SF; Darcy JM; Anderson VL; Krook JE; O'Connell MJ
    J Natl Cancer Inst; 2000 Jun; 92(12):1011-3. PubMed ID: 10861314
    [No Abstract]   [Full Text] [Related]  

  • 22. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TG-4010 Transgene.
    Cohen S; Kaufman HL
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1319-28. PubMed ID: 15648954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A decision analytic approach to a futility analysis of a phase II pharmaceutical study.
    Pallay A
    J Biopharm Stat; 2001 Nov; 11(4):209-25. PubMed ID: 12018776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Innovative strategies for early clinical R&D.
    Butz RF; Morelli G
    IDrugs; 2008 Jan; 11(1):36-41. PubMed ID: 18175261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myoblast transfer therapy.
    Law PK
    Lancet; 1993 Jan; 341(8839):247. PubMed ID: 8093534
    [No Abstract]   [Full Text] [Related]  

  • 27. Dalbavancin (Biosearch Italia/Versicor).
    Steiert M; Schmitz FJ
    Curr Opin Investig Drugs; 2002 Feb; 3(2):229-33. PubMed ID: 12020051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tresperimus (Laboratoires Fournier).
    Elices MJ
    Curr Opin Investig Drugs; 2001 Mar; 2(3):372-4. PubMed ID: 11575707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials.
    Sarzotti-Kelsoe M; Cox J; Cleland N; Denny T; Hural J; Needham L; Ozaki D; Rodriguez-Chavez IR; Stevens G; Stiles T; Tarragona-Fiol T; Simkins A
    PLoS Med; 2009 May; 6(5):e1000067. PubMed ID: 19536325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Innovative early development regulatory approaches: expIND, expCTA, microdosing.
    Robinson WT
    Clin Pharmacol Ther; 2008 Feb; 83(2):358-60. PubMed ID: 18091759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel endpoints and design of early clinical trials.
    Parulekar WR; Eisenhauer EA
    Ann Oncol; 2002; 13 Suppl 4():139-43. PubMed ID: 12401680
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase I trials: end the secrecy!
    Prescrire Int; 2010 Feb; 19(105):46. PubMed ID: 20455348
    [No Abstract]   [Full Text] [Related]  

  • 33. Inquiries in Britain uncover loopholes in drug trials.
    Rosenthal E
    N Y Times Web; 2006 Aug; ():A3. PubMed ID: 16909495
    [No Abstract]   [Full Text] [Related]  

  • 34. Regulatory reforms and GCP clinical trials with new drugs in India.
    Maggon K
    Clin Trials; 2004; 1(5):461-7. PubMed ID: 16279284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial Efficiency.
    Yeh JC; Huang P; Cohen KJ
    J Pediatr Hematol Oncol; 2016 Jul; 38(5):360-6. PubMed ID: 27164535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An overview of pharmacoepidemiology.
    Wertheimer AL; Andrews KB
    Pharm World Sci; 1995 May; 17(3):61-6. PubMed ID: 7550051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uncertain benefit: investigators' views and communications in early phase gene transfer trials.
    Henderson GE; Davis AM; King NM; Easter MM; Zimmer CR; Rothschild BB; Wilfond BS; Nelson DK; Churchill LR
    Mol Ther; 2004 Aug; 10(2):225-31. PubMed ID: 15294169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium.
    Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Wen PY; Fine HA; Mehta MP; DeAngelis LM; Lieberman FS; Cloughesy TF; Robins HI; Abrey LE; Prados MD;
    Neuro Oncol; 2008 Aug; 10(4):631-42. PubMed ID: 18559968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes.
    Greenbaum CJ; Harrison LC;
    Diabetes; 2003 May; 52(5):1059-65. PubMed ID: 12716733
    [No Abstract]   [Full Text] [Related]  

  • 40. Should terminally ill patients have the right to take drugs that pass phase I testing? Yes.
    Freireich EJ
    BMJ; 2007 Sep; 335(7618):478. PubMed ID: 17823187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.